Stock Watch: The Biotech Departure Lane From Europe
Exacting European Reimbursement Systems Cannot Be Mastered Without Outcomes Evidence
It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.
You may also be interested in...
With an approval nod from the EMA’s scientific committee for its fish oil product Vazkepa, launch plans for the EU for this “multi-billion dollar” opportunity are on track, says Amarin CEO.
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.